Cargando…

Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study

BACKGROUND: Multi-drug resistant tuberculosis (MDR-TB) is a major public health concern since diagnosis is often delayed, increasing the risk of spread to the community and health care workers. Treatment is prolonged, and the total cost of treating a single case is high. Diagnosis has traditionally...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Riordan, Philly, Schwab, Uli, Logan, Sarah, Cooke, Graham, Wilkinson, Robert J., Davidson, Robert N., Bassett, Paul, Wall, Robert, Pasvol, Geoffrey, Flanagan, Katie L.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526158/
https://www.ncbi.nlm.nih.gov/pubmed/18779863
http://dx.doi.org/10.1371/journal.pone.0003173
_version_ 1782158723256418304
author O'Riordan, Philly
Schwab, Uli
Logan, Sarah
Cooke, Graham
Wilkinson, Robert J.
Davidson, Robert N.
Bassett, Paul
Wall, Robert
Pasvol, Geoffrey
Flanagan, Katie L.
author_facet O'Riordan, Philly
Schwab, Uli
Logan, Sarah
Cooke, Graham
Wilkinson, Robert J.
Davidson, Robert N.
Bassett, Paul
Wall, Robert
Pasvol, Geoffrey
Flanagan, Katie L.
author_sort O'Riordan, Philly
collection PubMed
description BACKGROUND: Multi-drug resistant tuberculosis (MDR-TB) is a major public health concern since diagnosis is often delayed, increasing the risk of spread to the community and health care workers. Treatment is prolonged, and the total cost of treating a single case is high. Diagnosis has traditionally relied upon clinical suspicion, based on risk factors and culture with sensitivity testing, a process that can take weeks or months. Rapid diagnostic molecular techniques have the potential to shorten the time to commencing appropriate therapy, but have not been put to the test under field conditions. METHODOLOGY/PRINCIPAL FINDINGS: This retrospective case-control study aimed to identify risk factors for MDR-TB, and analyse the impact of testing for rifampicin resistance using RNA polymerase B (rpoB) mutations as a surrogate for MDR-TB. Forty two MDR-TB cases and 84 fully sensitive TB controls were matched by date of diagnosis; and factors including demographics, clinical presentation, microbiology findings, management and outcome were analysed using their medical records. Conventionally recognised risk factors for MDR-TB were absent in almost half (43%) of the cases, and 15% of cases were asymptomatic. A significant number of MDR-TB cases were identified in new entrants to the country. Using rpoB mutation testing, the time to diagnosis of MDR-TB was dramatically shortened by a median of 6 weeks, allowing patients to be commenced on appropriate therapy a median of 51days earlier than those diagnosed by conventional culture and sensitivity testing. CONCLUSIONS/SIGNIFICANCE: MDR-TB is frequently an unexpected finding, may be asymptomatic, and is particularly prevalent among TB infected new entrants to the country. Molecular resistance testing of all acid fast bacilli positive specimens has the potential to rapidly identify MDR-TB patients and commence them on appropriate therapy significantly earlier than by conventional methods.
format Text
id pubmed-2526158
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-25261582008-09-09 Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study O'Riordan, Philly Schwab, Uli Logan, Sarah Cooke, Graham Wilkinson, Robert J. Davidson, Robert N. Bassett, Paul Wall, Robert Pasvol, Geoffrey Flanagan, Katie L. PLoS One Research Article BACKGROUND: Multi-drug resistant tuberculosis (MDR-TB) is a major public health concern since diagnosis is often delayed, increasing the risk of spread to the community and health care workers. Treatment is prolonged, and the total cost of treating a single case is high. Diagnosis has traditionally relied upon clinical suspicion, based on risk factors and culture with sensitivity testing, a process that can take weeks or months. Rapid diagnostic molecular techniques have the potential to shorten the time to commencing appropriate therapy, but have not been put to the test under field conditions. METHODOLOGY/PRINCIPAL FINDINGS: This retrospective case-control study aimed to identify risk factors for MDR-TB, and analyse the impact of testing for rifampicin resistance using RNA polymerase B (rpoB) mutations as a surrogate for MDR-TB. Forty two MDR-TB cases and 84 fully sensitive TB controls were matched by date of diagnosis; and factors including demographics, clinical presentation, microbiology findings, management and outcome were analysed using their medical records. Conventionally recognised risk factors for MDR-TB were absent in almost half (43%) of the cases, and 15% of cases were asymptomatic. A significant number of MDR-TB cases were identified in new entrants to the country. Using rpoB mutation testing, the time to diagnosis of MDR-TB was dramatically shortened by a median of 6 weeks, allowing patients to be commenced on appropriate therapy a median of 51days earlier than those diagnosed by conventional culture and sensitivity testing. CONCLUSIONS/SIGNIFICANCE: MDR-TB is frequently an unexpected finding, may be asymptomatic, and is particularly prevalent among TB infected new entrants to the country. Molecular resistance testing of all acid fast bacilli positive specimens has the potential to rapidly identify MDR-TB patients and commence them on appropriate therapy significantly earlier than by conventional methods. Public Library of Science 2008-09-09 /pmc/articles/PMC2526158/ /pubmed/18779863 http://dx.doi.org/10.1371/journal.pone.0003173 Text en Philly et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
O'Riordan, Philly
Schwab, Uli
Logan, Sarah
Cooke, Graham
Wilkinson, Robert J.
Davidson, Robert N.
Bassett, Paul
Wall, Robert
Pasvol, Geoffrey
Flanagan, Katie L.
Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title_full Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title_fullStr Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title_full_unstemmed Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title_short Rapid Molecular Detection of Rifampicin Resistance Facilitates Early Diagnosis and Treatment of Multi-Drug Resistant Tuberculosis: Case Control Study
title_sort rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526158/
https://www.ncbi.nlm.nih.gov/pubmed/18779863
http://dx.doi.org/10.1371/journal.pone.0003173
work_keys_str_mv AT oriordanphilly rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT schwabuli rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT logansarah rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT cookegraham rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT wilkinsonrobertj rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT davidsonrobertn rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT bassettpaul rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT wallrobert rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT pasvolgeoffrey rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy
AT flanagankatiel rapidmoleculardetectionofrifampicinresistancefacilitatesearlydiagnosisandtreatmentofmultidrugresistanttuberculosiscasecontrolstudy